Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA. COPIKTRA (duvelisib), capsules for oral use Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-prescription
COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory CLL or SLL after at least two prior therapies. COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory FL after at least two prior systemic therapies. This indication is approved under accelerated approval based on overall response rate (ORR) [see Clinical Studies ( 14.2)]; continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
- generic_name
- duvelisib
- product_names
- duvelisib
- ndc
- 71779-125, 71779-115, 71779-125-04, 71779-125-02, 71779-125-01, 71779-115-03, 71779-115-02, 71779-115-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en